on SENSORION (EPA:ALSEN)
Leadership Transition at Sensorion amid Strategic Focus on Hearing Loss Therapies
Sensorion, a biotechnology company focused on hearing loss therapies, announced leadership changes effective immediately. CEO Nawal Ouzren steps down for personal reasons, with Chairman Amit Munshi assuming the role of Interim CEO. Ouzren will consult temporarily for a smooth transition, while the board searches for a permanent CEO.
Ouzren highlighted the company's strategic position, underpinned by recent €60 million financing led by Sanofi for advancing key pipeline assets like SENS-601, targeting GJB2 gene mutations linked to congenital deafness. Upcoming milestones include SENS-601 clinical trial applications and data from SENS-501 trials.
The transition occurs as Sensorion strengthens its focus on gene therapy and small molecule programs, aiming to address significant unmet needs in hearing loss disorders. The management vows to maintain developmental timelines and growth objectives.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SENSORION news